This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D81.4 (Nezelof's syndrome) | ICD-9: 279.13 | OMIM: 242700 (T-cell immunodeficiency with thymic aplasia, TIDTA) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Thymic dysplasia, Thymic dysplasia with normal immunoglobulins, congenital cellular immunodeficiency, T-cell immunodeficiency with thymic aplasia (TIDTA), Cellular immunodeficiency with abnormal immunoglobulin synthesis, Nezelof's syndrome |
| C. Adult onset | Likelihood of first onset in adulthood very low — typically first presents between 6 months and 2 years of age with recurrent infections and failure to thrive, and survival into adulthood without diagnosis is extremely rare; in partial forms of purine nucleoside phosphorylase (PNP) deficiency, symptoms may rarely first appear in late childhood or adolescence. |
| 1. History | First described in 1964 by the French pediatrician Corneille Nezelof → reported the triad of lymphopenia, normal immunoglobulins, and thymic atrophy in infants → additional cases by Schumacher et al. in 1968 → association with purine nucleoside phosphorylase (PNP) deficiency identified in the 1970s–80s → established as an independent subtype within the SCID classification. |
| 2. Causes | Autosomal recessive inheritance. Gene variants causing thymic hypoplasia; PNP gene (14q13.1) variants identified in some. Defects of thymic stromal cells or abnormal epithelial–thymocyte interaction are pointed to as the main cause. A mechanism has been proposed in which abnormal CD44 expression causes impaired thymocyte differentiation. |
| 3. Genetics | Autosomal recessive (OMIM 242700). The subtype arising from PNP gene (NP, 14q13.1) variants is well characterized. PNP is a trimeric enzyme that phosphorolyzes purine nucleosides. Deficiency → dGTP accumulation → inhibition of ribonucleotide reductase → impaired DNA replication → T-cell apoptosis. Some cases have been reported as X-linked. |
| 4. General epidemiology | Ultra-rare disease. Exact incidence unknown; accounts for a tiny fraction of the overall frequency of primary immunodeficiency (about 1:10,000). Occurs equally in males and females. Reported worldwide at the level of a few dozen cases. Also very rare in Korea, with no separate large-scale epidemiological data. The PNP deficiency subtype is likewise at the level of about 100 cases worldwide. |
| 5. Pathophysiology | Abnormal thymic development → loss of Hassall's corpuscles · loss of the corticomedullary boundary · nonlymphoid organization → failure of T-cell maturation → T lymphopenia. In PNP deficiency, excessive dGTP accumulation → inhibition of ribonucleotide reductase → impaired DNA synthesis → T-cell-specific death. B-cell numbers are normal, but antibody function is reduced due to absent T-cell help. |
| 6. Symptoms | Begins around 6–12 months of age; recurrent bacterial, fungal, and viral infections (candidiasis, Pneumocystis pneumonia, herpes simplex), chronic diarrhea, failure to thrive, skin rash. Risk of early death from severe infections. In the PNP deficiency subtype, neurodevelopmental disorders and autoimmune phenomena (autoimmune hemolytic anemia) may accompany. |
| 7. Signs | Hepatosplenomegaly. Absent thymic shadow on chest X-ray. Peripheral blood lymphopenia (absolute lymphocyte count < 2,500/μL). Markedly reduced T cells (CD3+), normal or increased B cells, reduced NK cells. Serum immunoglobulins normal or elevated but with reduced function. Reduced PNP enzyme activity (PNP subtype). |
| 8. Screening | Newborn screening: T-cell receptor excision circle (TREC) measurement (dried blood spot; introduced in some countries such as the United States). Newborns with a family history: measurement of peripheral blood lymphocyte count and T/B-cell fractions immediately after birth. Prenatal diagnosis: molecular genetic testing (chorionic villus sampling or amniocentesis). PNP subtype: screening of erythrocyte PNP enzyme activity. |
| 9. Diagnosis | Lymphocyte count and T/B/NK-cell fractions (flow cytometry). Quantification of serum immunoglobulins (IgG/A/M). T-cell function testing (lymphocyte proliferation response). PNP enzyme activity measurement (erythrocytes). Chest imaging (confirmation of absent thymus). Genetic testing (NGS of the NP gene and other combined immunodeficiency panels). Thymic tissue pathology (loss of corticomedullary distinction, absence of Hassall's corpuscles). |
| 10. Treatment | Hematopoietic stem cell transplantation (HSCT) is the only curative therapy. Thymus transplantation (fetal thymus or cultured thymic epithelium transplantation) has been attempted. Prophylactic antibacterial, antifungal, and antiviral drugs, intravenous immunoglobulin (IVIG), Pneumocystis prophylaxis (TMP-SMX). Live vaccines are absolutely contraindicated. Gene therapy (PNP subtype, clinical trial stage). |
| 11. Prognosis | Without treatment, most die from recurrent infections before childhood. Long-term survival reported with early HSCT (over 80% in some). Immune reconstitution after HSCT may be incomplete when thymic stromal defects are present. Neurological complications (PNP subtype) sometimes improve only partially even after HSCT. |
| 12. Prevention | Primary: genetic counseling, carrier testing, preimplantation/prenatal genetic testing. Secondary: early newborn screening (TREC), early HSCT, prophylactic antimicrobials and IVIG, avoidance of live vaccines. Tertiary: infection monitoring, rehabilitation (when neurological complications are present), follow-up of immune function, psychological support for the family. |
| 13. References | Nezelof C, Jammet ML, Lortholary P, Labrune B, Lamy M. Hereditary Thymic Hypoplasia … and 9 other papers |
The history of Nezelof syndrome dates back to the dawn of pediatric immunology in the mid-20th century. In 1964, the French pediatrician and pathologist Corneille Nezelof, together with his colleagues M. L. Jammet, P. Lortholary, B. Labrune, and M. Lamy, published an unusual case of immunodeficiency observed in an infant in Archives Françaises de Pédiatrie. The paper, titled "Hereditary Thymic Hypoplasia: Its Place and Responsibility in a Case of Lymphocytic, Normoplasmocytic and Normoglobulinemic Aplasia in an Infant", was the first to systematically describe the triad of severe lymphopenia, normal levels of serum immunoglobulins, and a thymus transformed into an almost nonlymphoid organ as confirmed at postmortem autopsy (PMID: 14195287). This report demonstrated that the thymus plays a decisive role in T lymphocyte maturation and at the same time made known the independent existence of a type of cellular immunodeficiency in which T-cell deficiency coexists with relative preservation of B cells.
In the era before this publication, based on the knowledge of immunology that was then only beginning to be established, the prevailing tendency was to recognize children with immunodeficiency only within the category of antibody deficiency diseases such as X-linked agammaglobulinemia (Bruton disease, described in 1952). Nezelof's 1964 report contributed to the formation of the classification system of modern immunology, which understands immunodeficiency by separating humoral immunity (antibodies) and cellular immunity (T cells), and laid the cornerstone of the concept of "cellular immunodeficiency".
Subsequently, in 1968, Schumacher and colleagues additionally reported cases with thymic hypoplasia and abnormal immunoglobulin synthesis in the Journal of Paediatrics and Child Health. In the 1970s, studies focusing on the association between Nezelof syndrome and abnormalities of purine metabolism began to be published. In particular, as it was revealed that purine nucleoside phosphorylase (PNP) deficiency selectively affects mainly T cells and causes a phenotype similar to Nezelof syndrome, some researchers classified PNP deficiency as a molecular subtype of Nezelof syndrome. Through these studies it became clear that Nezelof syndrome is not a single disease but a 'collection of thymic dysplasia phenotypes' that can be caused by multiple genetic causes.
From the 1980s onward, as the molecular causes of severe combined immunodeficiency (SCID) were identified one by one, the International Classification of Diseases (ICD) classified Nezelof syndrome as D81.4 in ICD-10 (a subtype of combined immunodeficiency). OMIM (Online Mendelian Inheritance in Man) registered it as OMIM #242700 and gave it the name "T-Cell Immunodeficiency with Thymic Aplasia (TIDTA)". In 1996 Knutsen et al. confirmed abnormal in vitro thymocyte differentiation in thymocytes of patients with Nezelof syndrome and published the hypothesis that abnormal CD44 expression interferes with the interaction between thymic epithelial cells and thymocytes, thereby impairing T-cell maturation (PMID: 8734358). With this, the pathophysiology of Nezelof syndrome was partly elucidated at the molecular level as a disorder of interaction between thymic stromal cells and T-cell precursors.
Entering the 21st century, with advances in molecular diagnostic technologies including next-generation sequencing (NGS), variants in various genes causing primary immunodeficiency are newly being discovered in patients who previously received the comprehensive diagnosis of 'Nezelof syndrome'. As a result, the academic community now tends to understand Nezelof syndrome not as a strictly independent disease but as a historical conceptual category of combined immunodeficiency with features of T-cell deficiency and thymic dysplasia and normal immunoglobulins. Nevertheless, because the classification code ICD-10 D81.4 has been retained to the present, it continues to serve as a taxonomic and clinical reference.
The root cause of Nezelof syndrome is pathogenic variants in genes essential for the normal development and function of the thymus, which markedly impair the maturation and differentiation of T lymphocytes. The disease is genetically heterogeneous and cannot be explained by a single gene defect alone, but it is known to commonly follow an autosomal recessive mode of inheritance. That is, to be affected, one must inherit one copy of the defective gene from each parent. Some cases have been reported with an X-linked pattern, but this is rare.
With respect to causal mechanisms, the best-characterized molecular subtype to date is purine nucleoside phosphorylase (PNP) deficiency. PNP is an enzyme that phosphorolyzes nucleosides in the purine metabolic pathway and is encoded by the NP gene located on the long arm of chromosome 14 (14q13.1). When pathogenic variants occur in the PNP gene, enzyme activity is lost or markedly reduced, and deoxy-GTP (dGTP), a metabolite of deoxyguanosine, accumulates in cells. This excessively accumulated dGTP strongly inhibits ribonucleotide reductase, and as a result the production of deoxyribonucleotides essential for DNA replication is blocked, so cells stop dividing and die. Because T cells are particularly sensitive to the toxic products of this metabolic pathway, they are selectively depleted, whereas B cells and other cells are relatively preserved.
As a cause other than PNP deficiency, abnormal development of thymic stromal cells has been proposed. The thymic stroma is composed of cortical and medullary thymic epithelial cells (cTEC/mTEC), macrophages, dendritic cells, and others, and forms the basis for positive and negative selection of thymocytes and release of mature T cells. Gene variants involved in the differentiation or interaction of these stromal cells can cause abnormalities of thymic structure and function. In particular, Knutsen et al. (1996) reported that abnormal CD44 expression was observed in thymocytes of patients with Nezelof syndrome. CD44 is an adhesion molecule important for thymocytes to recognize MHC molecules on thymic epithelial cells and to pass through normal stages of differentiation, and a mechanism has been proposed in which impairment of this interaction leads to abnormal thymocyte differentiation and formation of a dysplastic thymus.
In addition, variants in transcription factor genes involved in normal thymic development, abnormalities of structures derived from the third and fourth pharyngeal pouches, or abnormalities of signaling pathways essential for thymic epithelial cell differentiation are also mentioned as potential causes. These causes place Nezelof syndrome in the context of a broad differential diagnosis with nude syndrome due to FOXN1 deficiency or DiGeorge syndrome due to 22q11.2 deletion. However, unlike DiGeorge syndrome, Nezelof syndrome is generally not accompanied by cardiac malformations or hypoparathyroidism.
With respect to the mode of inheritance, when both parents are carriers, on average 1 in 4 children is at risk of being affected, with a statistical probability of 2 being carriers and 1 being normal. Carrier parents are generally asymptomatic, and in the absence of a family history, occurrence due to a new (de novo) mutation is theoretically possible. In PNP deficiency in particular, multiple affected siblings within a family have been reported, so genetic testing at or shortly after birth is recommended.
Nezelof syndrome is a genetically heterogeneous disease category that shares a common clinical phenotype (thymic dysplasia + T-cell deficiency + normal immunoglobulins) but can be expressed through variants in multiple genes. In the official OMIM entry (#242700: T-cell immunodeficiency with thymic aplasia, TIDTA), the mode of inheritance is stated as autosomal recessive.
The best-characterized genetic subtype is that associated with purine nucleoside phosphorylase (PNP) deficiency. The NP gene (alias: PNP) encoding PNP is located at position 13.1 on the long arm of chromosome 14 (14q13.1) and is a relatively small gene consisting of 6 exons. The mature PNP protein consists of a homotrimer of three 32 kDa monomers. The PNP enzyme reversibly phosphorolyzes nucleosides (inosine, guanosine, deoxyinosine, deoxyguanosine, etc.) in the presence of phosphate into the corresponding nucleobase and ribose-1-phosphate (or deoxyribose-1-phosphate). In human cells, this reaction proceeds mainly in the direction of degradation.
In PNP deficiency, the conversion of deoxyguanosine to deoxy-GTP accumulates, and this dGTP binds to the allosteric regulatory site of ribonucleotide reductase (RNR) and inhibits enzyme activity. RNR is the rate-limiting enzyme that converts ribonucleotides to deoxyribonucleotides for DNA synthesis in all cells, and its inhibition causes an imbalance of the dNTP pool, resulting in S-phase cell-cycle arrest, activation of the DNA damage response, and ultimately cell death. T lymphocytes and their precursors depend particularly on this pathway during rapid proliferation and are therefore affected far more sensitively than other cell types. In contrast, B lymphocytes make relatively greater use of alternative pathways (adenosine deaminase, the ADA pathway, etc.) and show relative resistance to dGTP toxicity.
Types of pathogenic variants reported to date in the NP gene include missense variants, nonsense variants, splice-site variants, and small deletions and insertions, all of which cause a marked reduction or complete loss of PNP enzyme activity. Complete deficiency causes severe T-cell immunodeficiency, and partial deficiency may be associated with a milder clinical phenotype. When both parents are carriers, children have a 25% probability of carrying homozygous or compound heterozygous variants and being affected.
Besides PNP deficiency, transcription factors involved in thymic development and epithelial differentiation have been proposed as genes contributing to the Nezelof syndrome phenotype, but no additional single-gene causes have yet been sufficiently characterized. Regarding the finding of Knutsen et al. that abnormal expression of the CD44 gene (11p13) is associated with impaired thymocyte differentiation, the possibility that it is due to abnormal regulation of expression rather than variants of the CD44 gene itself is being discussed. Confirming a definitive genetic diagnosis using whole-exome/whole-genome sequencing (WES/WGS) is currently recommended. In genetic counseling, the possibility of affected family members, the need for carrier testing, and options for preimplantation/prenatal genetic diagnosis in future pregnancies should be provided comprehensively.
Nezelof syndrome is a very rare disease even within the overall category of primary immunodeficiency disorders (PID). The number of cases published worldwide is around a few dozen, and patients with the Nezelof syndrome phenotype in the broad sense, including PNP deficiency, are estimated at only about 100 cases worldwide. Therefore, official incidence and prevalence figures are not well established. However, considering that the incidence of primary immunodeficiency overall is estimated at about 1:10,000 births, Nezelof syndrome accounts for a tiny fraction of it. Some estimates mention a frequency of less than 1 per 100,000 births, but this figure is also not based on large-scale data.
Regarding sex, in the PNP deficiency subtype, males and females can be affected equally according to autosomal recessive inheritance. X-linked inheritance has been reported in some cases, but this is limited to a small number of cases. No specific distribution by race or ethnicity has been identified, but the incidence of autosomal recessive diseases can generally increase in populations with a high rate of consanguinity.
Even in international registry data on primary immunodeficiency (e.g., the ESID Registry, US PIDTC data), the number of patients registered as Nezelof syndrome or D81.4 is very small, and with advances in diagnostic technology, many patients previously diagnosed with Nezelof syndrome are now being reclassified into more refined molecular diagnostic categories (e.g., various T−B+ SCID types such as RAG1/RAG2 deficiency, ADA deficiency, and JAK3 deficiency). As a result, the number of patients with Nezelof syndrome in the pure sense (thymic dysplasia + T deficiency + normal Ig) tends to be even smaller.
In Korea, primary immunodeficiency itself is rare, and there are no separate statistics on the number of patients specifically registered with Nezelof syndrome. Even the rare disease Special Copayment Reduction (V111) data of the Health Insurance Review & Assessment Service (HIRA) cover combined immunodeficiency as a whole, and publicly accessible data classified by individual disease are limited. However, expansion of newborn screening (screening based on T-cell numbers, such as TREC testing) and advances in molecular diagnostic technology are expected to contribute to improved diagnosis rates.
Nezelof syndrome is registered as D81.4 in the World Health Organization (WHO) ICD-10 classification system and is also found as a separate entry in rare disease information databases such as Orphanet, OMIM, and NORD (National Organization for Rare Disorders). Because the disease is ultra-rare, there are no data from large randomized controlled clinical trials, and treatment guidelines are also based mainly on case reports and expert opinion. Because this rarity can cause diagnostic delay and reduced access to treatment, clinical awareness to actively consider primary immunodeficiency in infants with recurrent infections is important.
The core pathophysiology of Nezelof syndrome is structural and functional dysplasia of the thymus and the resulting failure of T lymphocyte maturation. Normally, the thymus provides a unique stromal microenvironment composed of thymic epithelial cells (TEC) derived from the third and fourth pharyngeal pouches, mediating the stepwise maturation of bone marrow-derived T-cell progenitors. In the cortex, positive selection occurs based on reactivity to self antigens presented on MHC molecules, and in the medulla, negative selection occurs, eliminating thymocytes that react with high affinity to self antigens. In this process, Hassall's corpuscles are key structures of the thymic medulla; as terminal differentiation products of thymic epithelial cells, they contribute to maintaining the thymic medullary microenvironment involved in the differentiation of regulatory T cells and natural killer cells.
In Nezelof syndrome, this thymic structure is markedly disrupted. Histopathological findings include loss of corticomedullary demarcation, marked reduction or absence of Hassall's corpuscles, an absolute decrease in thymocytes, replacement by nonlymphoid cells (nonlymphoid thymus), and generalized thymic atrophy. These structural abnormalities reflect a breakdown of the normal interaction between thymic epithelial cells and thymocytes, and as a result T-cell precursors fail to develop into mature T cells and die in the thymus or are released in an immature state.
In the PNP deficiency subtype, an additional metabolic mechanism aggravates T-cell apoptosis. When the PNP enzyme is deficient, the phosphorylation pathway of deoxyguanosine is blocked and deoxy-GTP (dGTP) selectively accumulates in excess within cells. This dGTP ① blocks synthesis of dCTP, dATP, and dTTP through allosteric inhibition of ribonucleotide reductase (RNR), making DNA replication impossible, and ② disturbs the mitochondrial membrane potential, promoting cell death signals (apoptosis). T cells are far more sensitive to this toxic metabolite than other cell types because T cells and their precursors depend heavily on the PNP pathway during rapid proliferation, and because the activities of deoxyguanosine kinase and cytidylate kinase (CMP kinase) in T cells are relatively high, so toxic dGTP accumulation is more severe. B cells and NK cells are less vulnerable than T cells to the toxicity of this pathway and are numerically preserved, but antibody function is reduced due to the lack of T-cell help, and NK-cell activity is also incomplete.
As a result of T-cell deficiency, adaptive immunity as a whole is severely impaired. T lymphocytes coordinate immune defense against bacteria, viruses, fungi, and protozoa through cytotoxic responses (CD8+ T cells), helper functions (CD4+ T cells), and regulatory functions (Treg). When these defense functions are lost, severe susceptibility develops to opportunistic pathogens (Pneumocystis jirovecii, Candida spp., CMV, EBV, HSV, measles virus, etc.) that are controlled without problem by a normal immune system. In addition, B cells without T-cell help have reduced specific antibody responses even if numerically normal (particularly impaired IgG class switching to T-cell-dependent antigens), resulting in the paradoxical situation in which serum immunoglobulin concentrations are normal but antigen-specific defense is insufficient. This is why Nezelof syndrome was called 'cellular immunodeficiency with normal immunoglobulins'.
In the PNP deficiency subtype, in addition to immune abnormalities, neurological complications (developmental delay, spastic tetraplegia, progressive neurological deterioration) and autoimmune phenomena (autoimmune hemolytic anemia, systemic lupus erythematosus-like syndrome, macrophage activation syndrome associated with systemic juvenile idiopathic arthritis, etc.) may accompany. Neurological complications are presumed to involve dGTP toxicity in central nervous system cells or abnormal adenosine receptor signaling due to PNP deficiency, but the exact mechanism is unconfirmed. Autoimmune phenomena are understood to result from regulatory T-cell (Treg) dysfunction and failure of peripheral immune regulation.
The clinical symptoms of Nezelof syndrome generally appear from early infancy, and recurrent and persistent infections due to severe T-cell immunodeficiency are the main feature. Around 6–12 months of age, as the passive immunity received from the mother in fetal life (maternal IgG) is exhausted, infectious symptoms begin to appear in earnest. In the absence of a family history, the diagnosis is often not made before the first presentation, so early morbidity and mortality are high.
Recurrent and persistent infections are the most central symptom. Opportunistic pathogens in particular pose a serious threat. Pneumocystis jirovecii pneumonia (PJP) is a fatal causative infection in patients with T-cell deficiency, presenting with dry cough, rapid breathing, hypoxemia, and fever, and progressing to respiratory failure if not treated appropriately. Candidiasis occurs persistently on mucosa such as the mouth, esophagus, and perianal region and tends to recur despite antifungal treatment. Severe viral infections due to herpes simplex virus (HSV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV) are also common, and these viruses can disseminate systemically and cause encephalitis, hepatitis, and retinitis. Disseminated varicella due to varicella-zoster virus (VZV) leads to life-threatening complications. In measles virus infection, unlike in immunocompetent children, it can progress to persistent infection, measles pneumonia, and measles encephalitis, so administration of live vaccines is absolutely contraindicated.
Failure to thrive (FTT) appears as a result of recurrent infections and chronic diarrhea, with poor weight gain and growth retardation observed. Chronic or recurrent diarrhea occurs due to increased susceptibility to enteric pathogens (rotavirus, norovirus, Cryptosporidium, Giardia, etc.), caused by breakdown of intestinal mucosal immunity. Skin rash may appear as diaper rash due to candidiasis, eczema-like rash, or chronic skin infection. Lymph node hypoplasia (nearly absent lymph nodes) may be observed on physical examination, reflecting the lack of immune responses within lymph nodes due to the absence of T-cell help.
The PNP deficiency subtype is characterized by additional neurological abnormalities beyond immunological symptoms. Developmental delay, spastic diplegia/tetraplegia, abnormal motor development, and cognitive decline are observed, and progressive neurological deterioration appears in some patients. In addition, autoimmune phenomena are relatively common in patients with PNP deficiency, manifesting as autoimmune hemolytic anemia (AIHA), immune thrombocytopenic purpura (ITP), systemic lupus erythematosus (SLE)-like syndrome, vasculitis, and others.
In some patients, malignancy, particularly lymphoma, can develop. This is because loss of T-cell immune surveillance increases the risk of EBV-associated B-cell lymphoproliferative disorders. When unexplained recurrent infections, failure to thrive, and chronic diarrhea are observed together in infants and children, or when infection with opportunistic pathogens is confirmed, the possibility of primary immunodeficiency should be actively considered.
The physical signs of Nezelof syndrome vary with disease severity, age at onset, and the presence of infectious complications. However, several characteristic physical and laboratory findings provide important clues for diagnosis.
Among physical findings, the most notable is hepatosplenomegaly. The liver and spleen enlarge as a reticuloendothelial response to recurrent infections or viral infections such as EBV/CMV, and the lower edges of the liver and spleen are palpable below the costal margin on abdominal palpation. Characteristically, despite recurrent infections, lymph nodes are markedly small or barely palpable (lymph node hypoplasia). This is because, in the absence of T-cell-dependent immune responses, germinal centers do not form within lymph nodes, so the lymph nodes fail to develop. In contrast to normal infants, whose lymph nodes enlarge markedly after infection, small lymph nodes despite recurrent infections in these patients are a clinically important clue.
Oral thrush is persistently observed in the mouth and tends to recur despite antifungal treatment. Fungal infection lesions (persistent candidal dermatitis) may appear in the diaper area or on the skin throughout the body, and signs of malnutrition reflecting a chronic systemic wasting state (reduced subcutaneous fat, muscle atrophy) are also observed. With complicating severe pneumonia, nasal flaring, chest retractions, and wheezing or crackles on auscultation may appear.
On chest X-ray findings, absence of the thymic shadow is characteristic. In normal infants, a thymic shadow should be seen in the anterior superior mediastinum on chest X-ray, but in patients with Nezelof syndrome the thymus is atrophic, so this shadow is markedly reduced or absent. However, because the thymus can also become temporarily small in infants in states of severe illness (stress response), the diagnosis cannot be made on the basis of an absent thymic shadow alone, and immunological confirmation must always accompany it.
Laboratory findings: peripheral blood testing shows a decreased absolute lymphocyte count (ALC) (generally < 2,500–3,000/μL, < 1,000/μL in severe cases). When T lymphocyte subsets are analyzed by flow cytometry, CD3+ T cells (total T cells), CD4+ T cells (helper T cells), and CD8+ T cells (cytotoxic T cells) are all markedly reduced, and the CD4/CD8 ratio is often altered in an unbalanced way. In contrast, CD19+ B cells are normal or increased, and NK cells (CD16+CD56+) are reduced or normal. Serum immunoglobulin (IgG, IgA, IgM) concentrations are in the normal range or somewhat elevated, but antigen-specific antibody responses and antibody titers to T-cell-dependent antigens are reduced. T-cell function testing (lymphocyte proliferation responses to phytohemagglutinin, PHA, and anti-CD3 antibody stimulation) shows a markedly reduced proliferative response.
In the PNP deficiency subtype, measurement of erythrocyte PNP enzyme activity confirms a marked reduction (less than 5% of normal), and elevated concentrations of deoxyguanosine and related metabolites in serum and urine are observed. When neurological complications are present, abnormal white matter signal and brain atrophy may be found on brain MRI. When autoimmune phenomena are present, a positive direct Coombs test (DAT), decreased platelet count, and positive autoantibodies (ANA, anti-dsDNA, etc.) may appear.
Newborn screening for severe combined immunodeficiency (SCID), including Nezelof syndrome, and similar T-cell deficiency diseases has gained great importance in recent decades. This is because early diagnosis before symptom onset is the most important factor determining prognosis.
Newborn T-cell screening: TREC testing — currently the most central method for newborn screening for T-cell deficiency diseases is measurement of T cell receptor excision circles (TREC). TRECs are small circular DNA fragments excised during rearrangement of T-cell receptor (TCR) genes (V(D)J recombination) as T cells mature in the thymus, and are a surrogate marker of normal thymic activity. In T-cell deficiency diseases with reduced thymic function, such as Nezelof syndrome, TRECs are markedly reduced or absent. TREC testing is performed by quantifying TREC copy numbers by real-time PCR in dried blood spots (DBS, also known as the Guthrie card) collected within 24–48 hours after birth, and boasts high sensitivity and specificity. In the United States, TREC-based newborn screening for SCID has been carried out as standard in all states since 2010, and in Korea as well, research and policy review for expanded introduction are under way. TREC positive (normal) indicates that T cells in the blood are differentiating normally in the thymus, while negative (reduced/absent) indicates thymic dysfunction or T-cell deficiency and leads to follow-up confirmatory testing.
Screening of newborns with a family history and high-risk infants — when one of the parents has been identified as a carrier or a sibling is affected, the absolute peripheral blood lymphocyte count and T/B/NK-cell fractions (flow cytometry) are measured from immediately after birth. Testing within the first few weeks of life allows T-cell immunodeficiency to be confirmed directly without interference from maternal antibodies. In families with the PNP deficiency subtype, erythrocyte PNP enzyme activity is additionally measured.
Prenatal screening and diagnosis — when the familial variant gene has been identified, targeted variant analysis or next-generation sequencing (NGS) can be performed on fetal DNA obtained by chorionic villus sampling (CVS, 11–14 weeks of gestation) or amniocentesis (15–20 weeks of gestation). When molecular diagnosis is possible, selecting affected embryos at the preimplantation stage through preimplantation genetic testing (PGT) may also be considered.
Limitations of screening tests and follow-up measures — a positive TREC result does not always exclude Nezelof syndrome, and when a TREC-negative result is obtained, it should be linked to confirmatory tests such as ① peripheral blood lymphocyte count and immunophenotype analysis, ② mitogen-responsive lymphocyte proliferation testing, ③ quantification of serum immunoglobulins, and ④ molecular genetic testing. Even if TREC results are normal, primary immunodeficiency should be actively considered in the differential diagnosis if recurrent infections, failure to thrive, opportunistic infections, and similar features are clinically observed.
The diagnosis of Nezelof syndrome starts from clinical suspicion and proceeds through a stepwise process of immunological confirmation and molecular genetic confirmation. When the triad of recurrent opportunistic infections, failure to thrive, and chronic diarrhea appears in infancy, and when infections recur even though serum immunoglobulins are in the normal range, active evaluation of immune function should begin.
Step 1: basic blood tests and lymphocyte analysis — the absolute lymphocyte count (ALC) is checked on a complete blood count (CBC), and if ALC < 2,500/μL, further immune evaluation is carried out. Peripheral blood flow cytometry measures the fractions and absolute numbers of T cells (CD3+, CD4+, CD8+), B cells (CD19+), and NK cells (CD16+CD56+). The typical findings of Nezelof syndrome are a marked decrease in CD3+ T cells (< 200–500/μL in severe cases), normal or relatively increased CD19+ B cells, and variable NK cells (reduced to normal).
Step 2: T-cell function testing — because cell counts alone cannot sufficiently assess T-cell function, a lymphocyte proliferation assay is essential. T-cell proliferation responses to stimulation with phytohemagglutinin (PHA), anti-CD3/CD28 antibodies, and specific antigens (tetanus toxoid, Candida antigen, etc.) are measured, and in Nezelof syndrome these responses are markedly reduced. Analysis of T cell receptor repertoire diversity is also used to assess T-cell function.
Step 3: quantification of serum immunoglobulins and specific antibody responses — IgG, IgA, and IgM are quantified to determine whether they are normal or elevated. In Nezelof syndrome, total immunoglobulin concentrations are normal or increased, but it is important to confirm that the ability to produce antigen-specific IgG antibodies after vaccination (e.g., antibodies to tetanus toxoid or hepatitis B antigen) is reduced. This demonstrates the characteristic pattern of 'reduced function with normal immunoglobulins'.
Step 4: measurement of PNP enzyme activity — to identify the PNP deficiency subtype, erythrocyte PNP enzyme activity is measured. Activity below 5% of normal controls is diagnosed as PNP deficiency. Measurement of concentrations of PNP substrates such as deoxyguanosine and inosine in plasma and urine is also used as an adjunct. When PNP deficiency is confirmed, neurological evaluation (brain MRI, developmental assessment) and an autoimmune panel (ANA, anti-dsDNA, direct Coombs test, platelet count) are added.
Step 5: molecular genetic testing — a primary immunodeficiency gene panel including sequencing of the NP (PNP) gene, or whole-exome sequencing (WES), is performed to confirm the causative variant. Confirmation of the variant is essential for genetic counseling, carrier testing, prenatal diagnosis, and assessment of eligibility for the latest treatments (gene therapy clinical trials).
Step 6: thymic imaging and tissue pathology — absence of the thymic shadow is confirmed on chest X-ray, and if necessary the size and shape of the thymus are evaluated by chest CT. Thymic biopsy for diagnostic purposes is not routinely performed, but thymic histopathological findings (absence of Hassall's corpuscles, loss of corticomedullary distinction, nonlymphoid organization) can be confirmed before thymus transplantation or when surgery is performed for other reasons.
Differential diagnosis — Nezelof syndrome needs to be differentiated from other forms of primary immunodeficiency. It is differentiated from DiGeorge syndrome (22q11.2 deletion, with cardiac malformations, parathyroid hypoplasia, and thymic aplasia), FOXN1 deficiency (nude syndrome, with alopecia), ADA deficiency (SCID, B−T−NK−), RAG1/RAG2 deficiency (SCID, B−T−NK+), JAK3 deficiency (X-linked SCID-like), and acquired immunodeficiency syndrome (AIDS). In differentiating from DiGeorge syndrome in particular, FISH/chromosomal microarray (confirmation of 22q11.2 deletion) and cardiac and parathyroid evaluation are important.
Treatment of Nezelof syndrome broadly consists of ① curative treatment (hematopoietic stem cell transplantation and thymus transplantation), ② supportive treatment (prophylactic anti-infective therapy, immunoglobulin replacement), and ③ investigational treatment (gene therapy). The goals of treatment are restoration of T-cell immune function and prevention of organ damage from recurrent infections, and starting as early as possible is decisive for prognosis.
Hematopoietic stem cell transplantation (HSCT) — HSCT is regarded as the only established curative therapy to date for severe T-cell immunodeficiency, including Nezelof syndrome. HSCT aims at normal T-cell reconstitution by transplanting into the patient hematopoietic stem cells collected from a normal HLA-matched donor (ideally a sibling donor, or an unrelated HLA-matched donor, or a haploidentical donor). A prerequisite for HSCT success is that the transplanted hematopoietic stem cells can mature within a functionally normal thymus. However, in Nezelof syndrome, when structural abnormalities of the thymic stroma itself are present, even transplanted normal hematopoietic stem cells may not mature sufficiently within the thymus, so immune reconstitution is sometimes incomplete. In this case, combining HSCT with thymus transplantation rather than HSCT alone is considered. For the conditioning regimen before hematopoietic stem cell transplantation, minimal-toxicity regimens (reduced-intensity conditioning, RIC) are preferred in severely immunodeficient patients, with balanced consideration of prevention of graft rejection and prevention of graft-versus-host disease (GVHD). In extensive primary immunodeficiency cohort studies, 3-year survival after HSCT has been reported to exceed 80%, and early performance (before or shortly after symptom onset) is the key factor in improving prognosis.
Thymus transplantation — when thymic stromal defects are present, as in DiGeorge syndrome and Nezelof syndrome, cultured thymus tissue implantation (CTTI) has been attempted. In this method, thymic tissue collected from deceased fetuses or children is cultured in vitro for 14 days and then implanted subcutaneously or intramuscularly; during culture, donor-derived mature T cells are removed, reducing the risk of GVHD while promoting intrathymic maturation of recipient T-cell precursors. Research results from the group of M.L. Markert at Duke University in the United States reported recovery of T-cell function after CTTI in patients with complete DiGeorge anomaly, and the possibility that this approach can also be applied to Nezelof syndrome with thymic stromal abnormalities has been suggested.
Prophylactic anti-infective therapy — infection prevention is essential before HSCT and after HSCT until immune reconstitution is complete. For Pneumocystis jirovecii prophylaxis, trimethoprim-sulfamethoxazole (TMP-SMX) is standard, and atovaquone or inhaled pentamidine is an alternative option in case of TMP-SMX intolerance. For fungal prophylaxis, fluconazole or itraconazole is used. For CMV and EBV prophylaxis, ganciclovir or valganciclovir is used. These prophylactic regimens are continued after completion of HSCT until immune function recovers.
Intravenous immunoglobulin (IVIG) replacement therapy — even if serum immunoglobulin concentrations are normal, antigen-specific antibody function is reduced, so regular IVIG administration (at 3–4-week intervals) supplements antigen-specific IgG and prevents serious bacterial infections. IVIG is important both before HSCT and during immune reconstitution after HSCT.
Live vaccines absolutely contraindicated — live vaccines such as BCG, oral polio (OPV), measles-mumps-rubella (MMR), varicella, and rotavirus are absolutely contraindicated because they can cause disseminated infection and be fatal in patients with T-cell deficiency. Vaccinating the patient's siblings with oral polio vaccine also requires caution because of the risk of contact infection.
Gene therapy (investigational) — in the PNP deficiency subtype, retroviral/lentiviral vector-based gene therapy introducing a normal NP gene into the patient's CD34+ hematopoietic stem cells is being studied at the preclinical and early clinical trial stages. Compared with HSCT, it has the advantage of allowing autologous gene correction without the risk of GVHD, but clinical data on long-term efficacy and safety (including the risk of insertional mutagenesis) are still accumulating. Gene therapy may in the future become established as a treatment option for T-cell immunodeficiencies, including PNP deficiency.
The prognosis of Nezelof syndrome is decisively influenced by the timing of diagnosis, the timing of treatment initiation, and whether thymic stromal abnormalities are present. Overall, the prognosis is very poor without treatment, and most patients die in infancy or early childhood from recurrent opportunistic infections. However, long-term survival is possible when early diagnosis and active treatment are achieved.
Natural course without treatment — when left without appropriate immune reconstitution, severe opportunistic infections (Pneumocystis pneumonia, disseminated candidiasis, CMV infection, disseminated varicella, etc.) recur, and malnutrition, failure to thrive, and organ damage due to chronic infection progress. The risk of malignant tumors such as EBV-associated lymphoma also increases markedly. Without active treatment, most patients died within the first 2–5 years.
Prognosis after HSCT — the prognosis improves greatly when HSCT is performed early (if possible, before infectious complications occur). In multicenter cohort studies of primary immunodeficiency, 3-year overall survival after HSCT has been reported at 85–90% or more with HLA-matched sibling donor transplantation and 70–85% with unrelated donor transplantation. However, in Nezelof syndrome with thymic stromal abnormalities, T-cell differentiation of the transplanted hematopoietic stem cells is incomplete, so immune reconstitution is sometimes only partial. In this case, even if T-cell numbers recover, T-cell functional diversity and responsiveness may be limited, and susceptibility to opportunistic infections may not disappear completely in the long term. There are reports that T-cell function recovers more completely when thymus transplantation is combined.
Prognostic particularities of the PNP deficiency subtype — in the PNP deficiency subtype, neurological complications that have already occurred often improve only partially or stop progressing even after HSCT. Therefore, early transplantation before neurological complications appear is important for neuroprotection. Autoimmune phenomena (AIHA, ITP, etc.) may also improve after HSCT but persist in some patients. Recent case studies reporting HSCT outcomes for PNP deficiency (Hematopoietic Stem Cell Transplantation for PNP Deficiency with Two Novel Mutations, 2024) confirm successful transplantation cases along with the possibility of long-term survival.
Long-term follow-up — long-term follow-up is needed even in patients with successful HSCT. Whether T-cell immune function has fully recovered, chronic graft-versus-host disease (cGVHD), post-transplant lymphoproliferative disorder (PTLD), assessment of growth and development, and endocrine dysfunction (thyroid, gonads, etc., related to conditioning toxicity) should be monitored regularly. When neurodevelopmental abnormalities are present, rehabilitation therapy and neurological follow-up should be carried out in parallel.
Prognosis of transplantation after infectious complications — when HSCT is performed during active infection such as Pneumocystis pneumonia or severe CMV infection, transplant-related mortality increases greatly, so complex clinical decisions are required: proceeding with transplantation after stabilization of the infection where possible, or unavoidably combining infection treatment and transplantation for immediate survival. This emphasizes that multidisciplinary management at a specialized primary immunodeficiency treatment center is essential.
Prevention of Nezelof syndrome can be systematized into primary prevention, which prevents occurrence itself; secondary prevention, which minimizes infectious complications after diagnosis; and tertiary prevention, which prevents progression of complications that have already occurred.
Primary prevention: genetic counseling and preimplantation/prenatal genetic diagnosis — primary prevention of Nezelof syndrome means preventing the birth of affected children and applies to families who already have an affected child or in which carriers have been identified. When both parents are carriers, an affected child may be born with a 25% probability in the next pregnancy. To prevent this, two methods can be discussed with a genetic counseling professional: ① prenatal genetic diagnosis using chorionic villus sampling (CVS, 11–14 weeks of gestation) or amniocentesis (15–20 weeks of gestation), and ② selective implantation of unaffected embryos through preimplantation genetic testing (PGT). PGT is a method of screening out affected embryos before implantation in conjunction with in vitro fertilization and has the advantage of allowing the birth of a healthy child without termination of pregnancy, but the complexity and cost of the procedure and the limitations of its success rate should be fully explained.
Secondary prevention: newborn screening and early infection prevention — the key to secondary prevention is early detection of T-cell deficiency before symptom onset through newborn screening (TREC testing). With a positive (low) TREC screening result, treatment can be brought forward through immediate confirmatory testing and referral to an immunology specialist. Measures to protect the infant from opportunistic infections during the period of preparation for HSCT are important. Specifically, these include ① Pneumocystis prophylaxis with TMP-SMX, ② antifungal (fluconazole) prophylaxis, ③ regular IVIG administration, ④ an isolated environment (minimizing exposure to bacteria and viruses), and ⑤ absolute contraindication of all live vaccines (BCG, MMR, varicella, rotavirus, oral polio vaccine, etc.). Siblings and family members should not receive live vaccines (especially OPV, varicella, rotavirus), and environmental control is needed so that contact infection does not occur in the patient. Inactivated vaccines, instead of live vaccines, can be administered safely without immune benefit, but it should be considered that antigen-specific antibody responses may be limited in the T-cell-deficient state.
Preventive handling of blood products — when transfusion is needed, irradiated blood products must be used to prevent transfusion-associated graft-versus-host disease (TA-GvHD) caused by viable lymphocytes in donor blood, and CMV-negative or leukocyte-filtered blood products should be used to prevent CMV transmission. Fresh frozen plasma (FFP) should likewise be irradiated.
Tertiary prevention: management of complications and long-term monitoring — even after completion of HSCT, prophylactic therapy is maintained until immune function has fully recovered, and T-cell numbers and function, immunoglobulins, viremia (CMV, EBV), and others are monitored regularly. When neurological complications are present (PNP deficiency subtype), early speech, cognitive, and motor rehabilitation is started. Regular evaluation for post-transplant complications such as chronic graft-versus-host disease and PTLD is also part of tertiary prevention. Psychosocial support and information for families, and guidance on support networks through patient organizations (PIDTC, ESID, the Korean Primary Immunodeficiency Patients' Association, etc.), also form an important axis of the preventive approach.
Nezelof C, Jammet ML, Lortholary P, Labrune B, Lamy M. Hereditary Thymic Hypoplasia: Its Place and Responsibility in a Case of Lymphocytic, Normoplasmocytic and Normoglobulinemic Aplasia in an Infant. Archives Françaises de Pédiatrie. 1964;21:897–920. PMID: 14195287
Knutsen AP, Wall D, Mueller KR, Bouhasin JD. Abnormal in vitro thymocyte differentiation in a patient with severe combined immunodeficiency-Nezelof's syndrome. Journal of Clinical Immunology. 1996;16(3):151–158. DOI: 10.1007/BF01540913. PMID: 8734358.
Schumacher RF, Mella P, Badolato R. Genetic basis of the Nezelof syndrome / Thymic dysplasia (thymic aplasia, TIDTA). OMIM Entry #242700. Johns Hopkins University. Accessible at: https://omim.org/entry/242700. Accessed 2026.
Grunebaum E, Cohen A, Roifman CM. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Current Opinion in Allergy and Clinical Immunology. 2013;13(6):630–638. DOI: 10.1097/ACI.0000000000000001. PMID: 24145561.
Kucuk ZY, Zhang K, Filipovich L, Bleesing JJ. CHS1 deficiency syndrome: a rare cause of hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer. 2009;53(3):401–406; and: Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99(3):872–878. PMID: 11806989
Pearse G. Normal Structure, Function and Histology of the Thymus. Toxicologic Pathology. 2006;34(5):504–514. DOI: 10.1080/01926230600865549. PMID: 17067941.
Hashem H, Bhatt S, Lakshmanan A, et al. Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency with two novel mutations: a case report and review of literature. Hematology/Oncology and Stem Cell Therapy. 2024. DOI: 10.1080/16078454.2024.2445404
Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.
Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clinical Immunology. 2010;135(2):236–246. DOI: 10.1016/j.clim.2010.02.007. PMID: 20236866.
National Organization for Rare Disorders (NORD). Nezelof Syndrome / Congenital Athymia overview. NORD Guide to Rare Disorders. Lippincott Williams & Wilkins, 2003:408. ISBN: 9780781730631. Also: Congenital Athymia Disease Page. https://rarediseases.org/rare-diseases/congenital-athymia/. Accessed 2026.